Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Type B Insulin Resistance in Peru.

Zelada H, Gamarra D, Arbañil H, Manrique H.

Am J Med Sci. 2017 Mar;353(3):258-262. doi: 10.1016/j.amjms.2016.07.001. Epub 2016 Aug 30.

PMID:
28262212
2.

Detection of diabetic foot hyperthermia by infrared imaging.

Vilcahuaman L, Harba R, Canals R, Zequera M, Wilches C, Arista MT, Torres L, Arbañil H.

Conf Proc IEEE Eng Med Biol Soc. 2014;2014:4831-4. doi: 10.1109/EMBC.2014.6944705.

PMID:
25571073
3.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.

N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.

PMID:
23992601
4.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.

Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group.

Diabetes Obes Metab. 2009 Feb;11(2):167-76. doi: 10.1111/j.1463-1326.2008.01016.x.

PMID:
19125778
5.

Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.

Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group.

Diabetes Obes Metab. 2008 May;10(5):387-99. doi: 10.1111/j.1463-1326.2008.00873.x. Epub 2008 Mar 18.

PMID:
18355327

Supplemental Content

Loading ...
Support Center